DMAA
Drugs Made In America Acquisition Corp.Company Information
- Company Name
- Drugs Made In America Acquisition Corp.
- CIK
- CIK0002028614
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- DMAA: Nasdaq, DMAAR: Nasdaq, DMAAU: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 05 Real Estate & Construction
- SIC
- 6770
- SIC Description
- Blank Checks
- Ticker
- DMAA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-02-18
- Last sale
- 2025-01-29
- Shares purchased (TTM)
- 860,000
- Shares sold (TTM)
- 11,396,726
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 53,276,436
- Shares outstanding
- 20,095,314
- Ownership
- 265.12%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.47%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | - | - | 2 | 0 | 1 | 0 | 1 | ||||||
Assets Current | |||||||||||||
| Cash Equivalents At Carrying Value | - | - | 0 | - | - | - | 0 | ||||||
| Cash | - | - | 0 | - | 0 | 0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | - | 0 | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | |||||||||||||
| Deferred Costs | - | - | - | - | - | - | 1 | ||||||
| Assets Held In Trust Noncurrent | 147 | 242 | 240 | 238 | 235 | 233 | - | ||||||
| Assets Noncurrent | 147 | 242 | 240 | - | - | - | 1 | ||||||
Liabilities And Stockholders Equity | |||||||||||||
| Assets | 147 | 242 | 240 | 238 | 235 | 233 | 1 | ||||||
Liabilities Current | |||||||||||||
| Accounts Payable And Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | 0 | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 3 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
Liabilities Noncurrent | |||||||||||||
| Contract With Customer Liability Noncurrent | - | - | 7 | - | - | - | - | ||||||
| Deferred Compensation Liability Classified Noncurrent | 6 | 7 | - | 7 | - | - | - | ||||||
| Liabilities Noncurrent | 6 | 7 | 7 | - | - | - | - | ||||||
| Liabilities | 9 | 7 | 7 | 7 | 7 | 7 | 1 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 145 | 242 | 240 | 238 | 235 | 233 | - | ||||||
Stockholders Equity | |||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | - | - | - | - | - | - | 0 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | -1 | -1 | -1 | - | ||||||
| Retained Earnings Accumulated Deficit | -7 | -7 | -7 | -7 | -6 | -6 | -0 | ||||||
| Stockholders Equity | -7 | -7 | -7 | -7 | -7 | -7 | -0 | ||||||
| Liabilities And Stockholders Equity | 147 | 242 | 240 | 238 | 235 | 233 | 1 | ||||||
| Temporary Equity Shares Outstanding | 14 | 23 | 23 | 23 | 23 | 23 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 10.43 | - | - | - | 0.00 | ||||||
| Temporary Equity Redemption Price Per Share | 10.71 | 10.52 | - | 10.33 | 10.22 | 10.12 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 220 | 220 | 220 | 220 | 220 | 220 | 220 | ||||||
| Common Stock Shares Issued | 11 | 11 | 11 | 11 | 11 | 11 | 10 | ||||||
| Stock Issued During Period Shares Share Based Compensation Forfeited | 0 | 0 | - | - | - | - | - | ||||||
| Shares Outstanding | 11 | 11 | 11 | 11 | 11 | 11 | 10 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDrugs Made In America Acquisition Corp. (DMAA) — SEC Financial Statements & Analysis
Drugs Made In America Acquisition Corp. (DMAA) is a blank checks company. Drugs Made In America Acquisition Corp. trades on Nasdaq as: DMAA, DMAAR, DMAAU. Drugs Made In America Acquisition Corp. (DMAA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Drugs Made In America Acquisition Corp. carries a market cap of $214.02M, a P/E ratio of 35.11x, a P/B ratio of -28.90x, an enterprise value of $214.34M, and an EV/EBITDA multiple of -81.39x. On profitability, it posts a Return on Equity (ROE) of -83.73% and a Return on Assets (ROA) of 3.19%. Per share, it reports EPS of $0.30, diluted EPS of $0.30, free cash flow per share of $-0.03, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 0.02x, a quick ratio of 0.01x, working capital of $-2.88M, a debt-to-equity ratio of -1.23x, a debt ratio of 0.06, free cash flow of $-517.14K (TTM), and net debt of $329.72K. Figures sourced from SEC EDGAR.
- Market Cap
- $214.02M
- P/E TTM
- 35.11x
- EPS TTM
- $0.30
- P/B TTM
- -28.90x
- ROE TTM
- -83.73%
- ROA TTM
- 3.19%
- Debt To Equity
- -1.23x
- Free Cash Flow TTM
- $-517.14K
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Drugs Made In America Acquisition Corp. in?
Drugs Made In America Acquisition Corp. (DMAA) operates in the Blank Checks industry.
What exchange does DMAA trade on?
Drugs Made In America Acquisition Corp. (DMAA) trades on the Nasdaq.
When was Drugs Made In America Acquisition Corp. (DMAA)'s most recent SEC filing?
Drugs Made In America Acquisition Corp. (DMAA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is DMAA's market cap?
Drugs Made In America Acquisition Corp. (DMAA) has a market capitalization of $214.02M as of 2026-06-30.
What is DMAA's P/E ratio?
Drugs Made In America Acquisition Corp. (DMAA)'s trailing twelve month P/E ratio is 35.11x as of 2026-06-30.
What is DMAA's EPS (earnings per share)?
Drugs Made In America Acquisition Corp. (DMAA)'s trailing twelve month EPS is $0.30 as of 2026-06-30.
What is DMAA's ROE (return on equity)?
Drugs Made In America Acquisition Corp. (DMAA)'s trailing twelve month Return on Equity (ROE) is -83.73% as of 2026-06-30.
What is DMAA's ROA (return on assets)?
Drugs Made In America Acquisition Corp. (DMAA)'s trailing twelve month Return on Assets (ROA) is 3.19% as of 2026-06-30.
What is DMAA's EV/EBITDA?
Drugs Made In America Acquisition Corp. (DMAA)'s trailing twelve month EV/EBITDA is -81.39x as of 2026-06-30.